MDMA

2022 - 8 - 3

Post cover
Image courtesy of "Proactive Investors Australia"

Emyria initiates pre-clinical studies for MDMA-inspired analogues (Proactive Investors Australia)

Fibrotic diseases represent a major group of unmet medical needs and our early screening results indicate some analogues may have potent...

Preclinical studies are now commencing for leading drug candidates in each therapeutic area and the first preclinical program will explore the antifibrotic potential of a priority set of novel MDMA analogues. The healthcare stock has engaged the Institute of Respiratory Health (IRH) to conduct the studies as Emyria and UWA continue expanding one of the world’s largest libraries of novel MDMA-inspired analogues. Emyria Ltd (ASX:EMD) has kicked off a series of human cell-line pre-clinical studies to advance its MDMA-inspired drug discovery partnership with the University of Western Australia (UWA).

Post cover
Image courtesy of "The Market Herald"

Emyria (ASX:EMD) initiates preclinical studies for MDMA-inspired ... (The Market Herald)

Emyria (ASX:EMD) initiates a human cell-line preclinical study to advance its MDMA-inspired drug partnership with UWA.

As such, Emyria is aiming to develop new analogues inspired by MDMA. The Institute of Respiratory Health (IRH) has been engaged to conduct human cell-line studies and advance Emyria’s MDMA-inspired drug discovery partnership with UWA. Emyria (EMD) has initiated a human cell-line preclinical study to advance its MDMA-inspired drug partnership with the University of Western Australia.

Explore the last week